Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?
about
The current status of checkpoint inhibitors in metastatic bladder cancer.B7-H3 role in the immune landscape of cancer.Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma.Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models
P2860
Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?
@en
type
label
Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?
@en
prefLabel
Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?
@en
P2093
P2860
P1476
Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?
@en
P2093
Arnulf Stenzl
Christian Schwentner
Eva Comperat
Georgios Gakis
Johannes Mischinger
P2860
P2888
P356
10.1007/S11934-015-0532-8
P577
2015-09-01T00:00:00Z
P6179
1048534834